论文部分内容阅读
国家人力资源和社会保障部公布了国家医保谈判结果,用于治疗湿性年龄相关性黄斑变性(w AMD)的一线治疗药物雷珠单抗名列其中,被纳入国家医保乙类目录。在各省级医保目录落地实施后,根据政策,一般乙类药品报销比例可达70%~80%,意味着中国w AMD患者的医疗负担将被大大减轻,更多的患者将因此获益。抗血管内皮生长因子(抗VEGF)药物雷珠单抗(商品名:诺适得)2006年在美国上市,2011年在中国上市,改变了w AMD无有效治疗手段的局面。抗VEGF不仅可以阻断疾病进展,
The Ministry of Human Resources and Social Security announced the results of the national health care negotiation and ranked the first-line treatment drug ranibizumab for the treatment of wet age-related macular degeneration (w AMD), which is included in the national health insurance category B list. According to the policy, generally 70% to 80% of type B drugs are reimbursed after the implementation of provincial healthcare insurance catalogs. This means that the medical burden on AMD patients in China will be greatly reduced, and more patients will benefit from it. Anti-vascular endothelial growth factor (anti-VEGF) drug ranibizumab (trade name: Promos) was listed in the United States in 2006 and listed in China in 2011, changing the situation that w AMD has no effective treatment. Anti-VEGF can not only block the disease progression,